A Phase 1 interventional study of KL0011034 injection and Alfentanil Hydrochloride Injection in Chronic Pain, sponsored by Hunan Kelun Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Hunan Kelun Pharmaceutical Co., Ltd. (part of Sichuan Kelun Pharmaceutical Co.,Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Chronic Pain with a site in China — 14 open to participants now, 15 under way, 1 of them phase 3. Chronic Pain · China.
Among the 43 studies in Chronic Pain with a site in China, this one is the 32nd largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2026, is one of 8 in phase 1, and was the 42nd registered.
3,228 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
Browse Chronic Pain studies →14 of the 43 studies in Chronic Pain with a site in China are open now. Recruiting first, the newest first:
Shanghai Mental Health Center · Sites in China
Ages 18–80
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–64
Xuanwu Hospital, Beijing · Sites in China
Ages 50–90
The Second Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 34 interventional studies, 300 across the 9 observational. Of the 19 that completed or were terminated, 4 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Hunan Kelun Pharmaceutical Co., Ltd., one of the names counted as Sichuan Kelun Pharmaceutical Co.,Ltd.. Under that name alone:
Hunan Kelun Pharmaceutical Co., Ltd. is the lead sponsor of 9 studies on the registry; 6 are open to participants now.
Sichuan Kelun Pharmaceutical Co.,Ltd. has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Chronic Pain with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07323914Phase 3Xuanwu Hospital, BeijingClinical Analgesic Management in Dementia | 2027-01-01 |
| NCT06897007Beijing Tiantan HospitalChanges in Ciprofol Dosage in Patients With Insomnia Undergoing Intravenous Anesthesia | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Chronic Pain with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the pharmacokinetic interaction of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the safety and tolerability of KL0011034 injection in combination with alfentanil hydrochloride injection.To evaluate the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.
This study will be conducted among the participants with moderate-to-severe non-cancerous chronic pain, aiming to evaluate the drug-drug interactions between KL0011034 injection and alfentanil hydrochloride injection. The study consists of two parts:
Part 1 trial:
A single-center, randomized, open, parallel design is adopted to evaluate the safety, tolerability and pharmacodynamic characteristics of the combined use of KL0011034 injection and alfentanil hydrochloride injection.
It is planned to enroll 9 patients with moderate-to-severe non-cancerous chronic pain. All participants will be randomly assigned to one of the three dose groups in a 1:1:1 ratio, with 3 participants in each group. They will complete a single combined administration and undergo pharmacodynamic and safety evaluations.
Based on the results of Part 1 trial, KL0011034 injection will select the maximum dose with acceptable safety among the three doses for the second part of the study.
Part 2 trial:
A single-center, randomized, open, three-sequence, three-period crossover trial design is adopted to evaluate the PK interactions, safety and tolerability of the combined use of KL0011034 injection and alfentanil hydrochloride injection, as well as the effect of alfentanil hydrochloride injection on the pharmacodynamics of KL0011034 injection.
It is planned to enroll 18 patients with moderate-to-severe non-cancerous chronic pain. All participants will be randomly assigned to one of the three sequences A, B, and C in a 1:1:1 ratio, with 6 participants in each sequence. They will complete three periods of open administration and undergo PK blood sampling, pharmacodynamic and safety evaluations, with a 3-day washout period for each period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1, 6 participants will receive KL0011034 injection; Period 2, 6 participants will receive Alfentanil Hydrochloride Injection; Period 3, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Period 1, 6 participants will receive Alfentanil Hydrochloride Injection; Period 2, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 3, 6 participants will receive KL0011034 injection;
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Period 1, 6 participants will receive combination of Alfentanil Hydrochloride Injection and KL0011034 injection; Period 2, 6 participants will receive KL0011034 injection; Period 3, 6 participants will receive Alfentanil Hydrochloride Injection;
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Intravenous injection, single dose
Intravenous injection, single dose
Number of reported Adverse Events
Safety and tolerability was assessed by the number of volunteers with adverse events.
Time frame: 24 hours post-dose for each period
PK parameter Cmax in plasma
Maximum peak plasma concentration (Cmax) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. Cmax of Alfentanil combining with or without KL0011034 injection.
Time frame: 24 hours post-dose for each period
PK parameter Tmax in plasma
Time of Cmax (Tmax) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. Tmax of Alfentanil combining with or without KL0011034 injection.
Time frame: 24 hours post-dose for each period
PK parameter AUC0-t in plasma
Area under the concentration-time curve (AUC0-t) from time zero to time "t" of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. AUC0-t of Alfentanil combining with or without KL0011034 injection.
Time frame: 24 hours post-dose for each period
PK parameter AUC0-∞ in plasma
AUC from time zero to infinity (AUC0-∞) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. AUC0-∞ of Alfentanil combining with or without KL0011034 injection.
Time frame: 24 hours post-dose for each period
PK parameter t1/2 in plasma
Terminal-phase elimination half-life (t1/2) of KL0011034 and its metabolite combining with or without Alfentanil Hydrochloride Injection. t1/2 of Alfentanil combining with or without KL0011034 injection.
Time frame: 24 hours post-dose for each period
Modified Observer's Assessment of Alertness Sedation (MOAA/S) scale
MOAA/S is a commonly used clinical sedation assessment scale, ranging from 0 to 5, which helps clinicians determine the level of sedation in patients. A score of 5 indicates full consciousness, whereas a score of 0 indicates deep coma. Lower scores correspond to deeper levels of sedation.
Time frame: Day 1 for each period
Electroencephalogram bispectrality index (BIS) monitoring
BIS is the most widely used method for the continuous monitoring of sedation depth in clinical anesthesia. BIS values range from 0 to 100, where 100 represents complete wakefulness and 0 indicates complete cortical electrical inhibition.
Time frame: Day 1 for each period
Loss of eyelash reflex
The eyelash reflex is a commonly used clinical method to assess the level of consciousness in patients. Gentle stimulation of the eyelashes with a cotton swab normally elicits a blink; absence of this response indicates loss of the eyelash reflex.
Time frame: Day 1 for each period
Modified Aldrete Scoring (Aldrete) Scale
The Modified Aldrete Score is the most widely used standardized tool for assessing discharge readiness from post-anesthesia care unit (PACU). It evaluates five parameters: activity, respiration, blood pressure consciousness, and SpO₂. Ranging from 0 to 10, the higher the score, the better the quality of recovery.
Time frame: Day 1 for each period
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2026 to primary completion in Aug 2026, 0 months.
Of 27 industry-sponsored phase 1 interventional studies under Chronic Pain, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 12. This study's 0 months is below that.
Counting every sponsor, half of 60 studies reached it within 12 months; a quarter within 6 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: KL0011034 · Alfentanil
Hunan Kelun Pharmaceutical Co., Ltd. →